Clinical efficacy and security of glycyrrhizic acid preparation in the treatment of anti-SARS-CoV-2 drug-induced liver injury: a protocol of systematic review and meta-analysis
Introduction COVID-19 is a highly infectious acute pneumonia. Glycyrrhizic acid preparation (GAP) has been found to have hepatoprotective and antiviral effects, but there is no supporting evidence on its efficacy and security for patients with COVID-19.Methods and analysis The systematic review meth...
Main Authors: | Rongtao Ying, Mei Chen, Xia Tian, Wenfan Gan, Yisen Nie, Yongji Tan, Junli Chen, Chuantao Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2021-07-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/11/7/e051484.full |
Similar Items
-
Study of Glycyrrhizic Acid and Azasugars:Synthesis of Glycyrrhizic Acid Derivatives as the Anti-SARS-CoV AgentsSynthesis of Azasugars and the Reactions of Saccharides in Aqueous Solution
by: Chong-Shun Jian, et al.
Published: (2005) -
Glycyrrhizic Acid for COVID-19: Findings of Targeting Pivotal Inflammatory Pathways Triggered by SARS-CoV-2
by: Wenjiang Zheng, et al.
Published: (2021-06-01) -
Glycyrrhizic Acid in the Treatment of Liver Diseases: Literature Review
by: Jian-yuan Li, et al.
Published: (2014-01-01) -
Glycyrrhizic acid improving the liver protective effect by restoring the composition of Lactobacillus
by: Tianjie Yuan, et al.
Published: (2019-01-01) -
Extraction of Glycyrrhizic Acid and Glabridin from Licorice
by: Kyung Ho Row, et al.
Published: (2008-04-01)